Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 9/20 | 0.46 |
| ▸ | CA2 | P00918 | 9/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22960721 | 1.00 | MEN1 (0.59) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL25291828 | 0.95 | MEN1 (0.65) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL25255789 | 0.95 | MEN1 (0.65) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL8296524 | 0.87 | MEN1 (0.54) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL16350524 | 0.86 | MEN1 (0.48) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL20364081 | 0.85 | MEN1 (0.58) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL1748939 | 0.85 | MEN1 (0.58) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL6357111 | 0.85 | MEN1 (0.58) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL4107078 | 0.85 | TDP1 (0.61) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL30915267 | 0.85 | TDP1 (0.61) | MEN1KMT2AGAATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| US-20210198278-A1 | SECO MACROLIDE COMPOUNDS | SELVITA D.O.O. (HR) | 2021-07-01 | — | — | US | disclosed |
| US-10919910-B2 | Seco macrolide compounds | FIDELTA D.O.O. (HR) | 2021-02-16 | — | — | US | disclosed |
| EP-0429611-B1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | ROCHE DIAGNOSTICS GMBH (DE) | 2001-02-28 | — | — | EP | disclosed |
| EP-0429611-A1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | Roche Diagnostics GmbH (DE) | 1991-06-05 | — | — | EP | disclosed |
| WO-1990015798-A1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198278-A1 | SECO MACROLIDE COMPOUNDS | SEC61B, SEC16A, SEC61A1 | MEN1 1732/4885KMT2A 4255/4885GAA 1392/4885 |
| US-10919910-B2 | Seco macrolide compounds | SEC61B, SEC16A, SEC61A1 | MEN1 1732/4885KMT2A 4255/4885GAA 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.